GIP
ADMS

Granite Investment Partners’s Adamas Pharmaceuticals ADMS Stock Holding History

Granite Investment Partners’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-22,731
Closed -$141K – 377
2019
Q2 		$141K Sell
22,731
-20,004
-47% -$115K 0.01% 340
2019
Q1 		$304K Buy
+42,735
New +$384K 0.02% 327

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Granite Investment Partners's ADMS Position: Q3 2019 in Review

Granite Investment Partners sold out of Adamas Pharmaceuticals (ADMS) in Q3 2019, closing a stake of 22,731 shares — an estimated $141K sold.

Granite Investment Partners first reported a position in ADMS in Q1 2019 and held it in 2 quarters. The position peaked at $304K in Q1 2019. 87 funds tracked by Wall St. Rank hold ADMS as of Q3 2019.

  • Granite Investment Partners reported no remaining Adamas Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Granite Investment Partners sold 22,731 Adamas Pharmaceuticals shares in Q3 2019, an estimated $141K.
  • Granite Investment Partners first reported a position in Adamas Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Granite Investment Partners's Adamas Pharmaceuticals position peaked at $304K in Q1 2019.
  • 87 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2019.

Based on Granite Investment Partners's 13F filing for Q3 2019, filed 12 Nov 2019.